Servier Laboratories (Groupe Servier)

Servier is a leading independent, non-profit French pharmaceutical company founded in 1954 by Dr. Jacques Servier. Unlike most major pharma companies, Servier is governed by a non-profit foundation, which reinvests all profits into research and development. The company focuses on oncology, cardiology, metabolism, neuroscience, and immuno-inflammatory diseases, while also maintaining a strong presence in generics through its subsidiary Biogaran.

Mission and Vision

Mission: To commit to therapeutic progress for the benefit of patients, focusing on areas with high unmet medical needs.
Vision: To be recognized as a trusted global innovator in pharmaceuticals, guided by science and patient needs, not shareholder demands.

Products and Services

Therapeutic Areas:
- Oncology: Expanding pipeline in solid tumors and hematologic cancers.
- Cardiology & Metabolism: Treatments for hypertension, diabetes, and lipid disorders.
- Neuroscience & Immunology: Research into depression, neurodegenerative diseases, and immune-inflammatory conditions.
Generics: Through Biogaran, a leading generics company in France.
Research & Development: Heavy investment in oncology and precision medicine.

Growth and Innovation
Servier is undergoing a transformation to become a leading player in oncology, which now represents a major portion of its R&D. As a foundation-governed company, Servier has the unique advantage of reinvesting long-term in science rather than focusing on short-term profits. This model has allowed it to maintain independence and expand into over 150 countries.

Global Impact
With medicines used by millions of patients worldwide, Servier combines a strong European base with a significant global footprint. Its non-profit structure ensures that all earnings go back into research, sustainability, and patient access initiatives. Servier also engages in global health partnerships, particularly in underserved regions.